Markj Levis News Today

Harry P. Erba, MD, PhD, discusses the implications of the FDA approval of quizartinib for the treatment of patients with FLT3-ITD–mutated AML, the background and key findings of the QuANTUM-First study, and how to now navigate between potential treatment options for this patient population.

Patients with acute myeloid leukemia and who have minimal residual disease following hematopoietic cell transplantation have a reduced risk of relapse with gilteritinib maintenance therapy.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.